41,109 TransMedics Group, Inc. $TMDX Shares Sold by Zevenbergen Capital Investments LLC

Zevenbergen Capital Investments LLC reduced its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 13.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 267,282 shares of the company’s stock after selling 41,109 shares during the quarter. Zevenbergen Capital Investments LLC owned approximately 0.77% of TransMedics Group worth $22,305,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. Silvant Capital Management LLC bought a new position in shares of TransMedics Group during the 2nd quarter worth $26,000. North Star Investment Management Corp. purchased a new position in shares of TransMedics Group in the first quarter worth about $30,000. Ascentis Independent Advisors bought a new stake in shares of TransMedics Group in the first quarter valued at approximately $30,000. State of Wyoming purchased a new stake in shares of TransMedics Group during the 2nd quarter valued at approximately $31,000. Finally, Ancora Advisors LLC bought a new position in TransMedics Group in the 2nd quarter worth approximately $33,000. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Price Performance

NASDAQ TMDX traded down $2.07 during trading on Thursday, reaching $79.00. The company’s stock had a trading volume of 949,379 shares, compared to its average volume of 1,008,943. The firm has a fifty day moving average of $85.98 and a 200 day moving average of $83.97. TransMedics Group, Inc. has a one year low of $60.10 and a one year high of $156.00. The stock has a market capitalization of $2.73 billion, a PE ratio of 20.31, a P/E/G ratio of 1.10 and a beta of 1.94. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). The business had revenue of $189.95 million for the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm’s revenue for the quarter was up 20.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.92 EPS. Analysts expect that TransMedics Group, Inc. will post 1.46 EPS for the current fiscal year.

Insider Transactions at TransMedics Group

In related news, Director David Weill bought 1,336 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was bought at an average cost of $81.63 per share, for a total transaction of $109,057.68. Following the completion of the transaction, the director owned 16,392 shares of the company’s stock, valued at approximately $1,338,078.96. The trade was a 8.87% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 6.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TMDX. TD Cowen reaffirmed a “buy” rating and issued a $120.00 price target on shares of TransMedics Group in a report on Tuesday, September 8th. Canaccord Genuity Group restated a “buy” rating and issued a $124.00 target price on shares of TransMedics Group in a research note on Tuesday, June 30th. Weiss Ratings upgraded TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Barclays assumed coverage on shares of TransMedics Group in a report on Wednesday. They issued an “overweight” rating and a $120.00 price target on the stock. Finally, Zacks Research lowered shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research report on Monday, July 6th. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, TransMedics Group currently has a consensus rating of “Hold” and an average price target of $121.00.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company that develops organ transplant systems designed to preserve and assess donated organs outside the body before transplantation. Its primary platform, the Organ Care System (OCS), uses warm perfusion technology to circulate oxygenated blood and nutrients through organs, helping maintain organ function during transport and potentially expanding the pool of organs available for transplant.

The company offers OCS solutions for heart, lung and liver transplantation.